Elutia Inc. (ELUT) stock
ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3011% below fair value
$0.85+0.03 (+3.77%)
Close on Nov 17, 2026Market cap $37.82MP/E –Yield –
Elutia total assets
Total assets on the balance sheet at the end of each period.
Elutia's total assets was $43.65M at Jun 30, 2026. For fiscal 2025 it was $62.35M, up 72.6% from the year before. The highest annual figure on record is $82.81M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.35M | +72.6% |
| FY2024 | Dec 31, 2024 | $36.13M | -16.8% |
| FY2023 | Dec 31, 2023 | $43.43M | -36.9% |
| FY2022 | Dec 31, 2022 | $68.84M | +2.5% |
| FY2021 | Dec 31, 2021 | $67.17M | -18.9% |
| FY2020 | Dec 31, 2020 | $82.81M | +85.0% |
| FY2019 | Dec 31, 2019 | $44.77M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $43.65M | +29.0% |
| Q1 FY2026 | Mar 31, 2026 | $55.21M | +40.5% |
| Q4 FY2025 | Dec 31, 2025 | $62.35M | +72.6% |
| Q3 FY2025 | Sep 30, 2025 | $29.41M | -39.3% |
| Q2 FY2025 | Jun 30, 2025 | $33.85M | -19.2% |
| Q1 FY2025 | Mar 31, 2025 | $39.30M | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | $36.13M | -16.8% |
| Q3 FY2024 | Sep 30, 2024 | $48.41M | -11.3% |
| Q2 FY2024 | Jun 30, 2024 | $41.90M | -19.9% |
| Q1 FY2024 | Mar 31, 2024 | $35.36M | -41.7% |
| Q4 FY2023 | Dec 31, 2023 | $43.43M | -36.9% |
| Q3 FY2023 | Sep 30, 2023 | $54.58M | +3.3% |
| Q2 FY2023 | Jun 30, 2023 | $52.33M | -12.7% |
| Q1 FY2023 | Mar 31, 2023 | $60.63M | -9.7% |
| Q4 FY2022 | Dec 31, 2022 | $68.84M | +14.9% |
| Q2 FY2022 | Jun 30, 2022 | $52.85M | -24.2% |
| Q1 FY2022 | Mar 31, 2022 | $59.93M | -19.2% |
| Q4 FY2021 | Dec 31, 2021 | $67.17M | -18.9% |
| Q3 FY2021 | Sep 30, 2021 | $59.90M | +29.8% |
| Q2 FY2021 | Jun 30, 2021 | $69.70M | +55.7% |
| Q1 FY2021 | Mar 31, 2021 | $74.21M | – |
| Q4 FY2020 | Dec 31, 2020 | $82.81M | – |
| Q3 FY2020 | Sep 30, 2020 | $46.14M | – |
| Q4 FY2019 | Dec 31, 2019 | $44.77M | – |
See a number that looks wrong?